{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:44:48Z","timestamp":1792251888277,"version":"4.4.0"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"abstract":"<jats:p>\n                    CKD affects more than 850 million individuals worldwide and is a major contributor to global morbidity and premature mortality. Most CKD burden arises from early stages of disease, when reductions in eGFR are modest and symptoms often absent. CKD and cardiovascular disease share a bidirectional relationship mediated by common risk factors and pathophysiologic pathways. Even mild reductions in eGFR or low-grade albuminuria are associated with adverse cardiovascular outcomes. Accumulating evidence suggests that primary prevention of CKD may be feasible. In this narrative review, we examine pharmacologic strategies with potential relevance to preventing incident CKD among individuals without established disease at baseline, defined by eGFR \u226560 ml\/min per 1.73 m\n                    <jats:sup>2<\/jats:sup>\n                    and absence of albuminuria. Evidence derives largely from secondary and\n                    <jats:italic toggle=\"yes\">post hoc<\/jats:italic>\n                    analyses of cardiovascular outcome trials evaluating sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, mineralocorticoid receptor antagonists, and angiotensin receptor-neprilysin inhibitors. Across multiple trials, sodium-glucose cotransporter 2 inhibitors consistently attenuate eGFR decline and reduce incident or progressive albuminuria, including among participants without CKD at baseline, providing the most consistent evidence supporting a potential role in primary prevention. Glucagon-like peptide-1 receptor agonists demonstrate similar but less uniform effects, driven largely by reductions in albuminuria. Evidence supporting mineralocorticoid receptor antagonists and angiotensin receptor-neprilysin inhibitors for primary prevention is more limited and less consistent. Although randomized trials specifically designed to evaluate incident CKD are lacking, these findings suggest that therapies developed for cardiometabolic disease may modify early markers of kidney injury. A selective, risk-based approach to earlier intervention may represent an emerging strategy to preserve kidney health and reduce long-term cardiovascular and renal risk.\n                  <\/jats:p>","DOI":"10.2215\/cjn.0000001170","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:01:02Z","timestamp":1785772862000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Primary Prevention of CKD for Heart and Kidney Health"],"prefix":"10.2215","author":[{"given":"Tenzin","family":"Dorjee","sequence":"first","affiliation":[{"name":"Division of Cardiology, University of British Columbia, Vancouver, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1286-2014","authenticated-orcid":false,"given":"Nathanial","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of British Columbia, Vancouver, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Moghaddam","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of British Columbia, Vancouver, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0725-150X","authenticated-orcid":false,"given":"Mark","family":"Elliott","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, Canada"},{"name":"Division of Nephrology, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-8401","authenticated-orcid":false,"given":"Adeera","family":"Levin","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, Canada"},{"name":"Division of Nephrology, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"11","key":"B1-20261017","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/ndt\/gfz174","article-title":"A single number for advocacy and communication\u2014worldwide more than 850 million individuals have kidney diseases","volume":"34","author":"Jager","year":"2019","journal-title":"Nephrol Dial Transplant."},{"issue":"10518","key":"B2-20261017","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the global burden of disease study 2023","volume":"406","author":"Mark","year":"2025","journal-title":"Lancet."},{"issue":"17","key":"B4-20261017","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation."},{"issue":"9731","key":"B5-20261017","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet."},{"issue":"7","key":"B6-20261017","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"8","key":"B7-20261017","doi-asserted-by":"crossref","first-page":"e003825","DOI":"10.1161\/CIRCHEARTFAILURE.116.003825","article-title":"Heart failure increases the risk of adverse renal outcomes in patients with normal kidney function","volume":"10","author":"George","year":"2017","journal-title":"Circ Heart Fail."},{"issue":"1","key":"B8-20261017","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2369-13-77","article-title":"The risk for chronic kidney disease in patients with heart diseases: a 7-year follow-up in a cohort study in Taiwan","volume":"13","author":"Liu","year":"2012","journal-title":"BMC Nephrol."},{"issue":"11","key":"B9-20261017","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation."},{"issue":"20","key":"B10-20261017","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation."},{"issue":"special 1","key":"B11-20261017","first-page":"e250405","article-title":"Cardio-kidney-metabolic (CKM) framework: a nephrologist's perspective","volume":"70","author":"Moura","year":"2025","journal-title":"Arch Endocrinol Metab."},{"issue":"7","key":"B12-20261017","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","article-title":"Chronic kidney disease and the global public health agenda: an international consensus","volume":"20","author":"Francis","year":"2024","journal-title":"Nat Rev Nephrol."},{"issue":"4S","key":"B13-20261017","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int."},{"issue":"1","key":"B14-20261017","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"B15-20261017","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"New Engl J Med."},{"issue":"22","key":"B16-20261017","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"New Engl J Med."},{"issue":"7","key":"B17-20261017","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"New Engl J Med."},{"issue":"15","key":"B18-20261017","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"New Engl J Med."},{"issue":"2","key":"B19-20261017","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"New Engl J Med."},{"issue":"24","key":"B20-20261017","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"New Engl J Med."},{"issue":"15","key":"B21-20261017","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"New Engl J Med."},{"issue":"15","key":"B22-20261017","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"New Engl J Med."},{"issue":"16","key":"B23-20261017","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"New Engl J Med."},{"issue":"21","key":"B24-20261017","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"New Engl J Med."},{"issue":"12","key":"B25-20261017","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"New Engl J Med."},{"issue":"10","key":"B26-20261017","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.2337\/dc22-0382","article-title":"Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial","volume":"45","author":"Mosenzon","year":"2022","journal-title":"Diabetes Care."},{"issue":"10","key":"B27-20261017","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2215\/CJN.14901219","article-title":"Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: post hoc: analysis of a randomized, double-blind, placebo-controlled, multinational trial","volume":"15","author":"Levin","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"issue":"6","key":"B28-20261017","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial","volume":"64","author":"Cherney","year":"2021","journal-title":"Diabetologia."},{"issue":"1","key":"B29-20261017","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.ajkd.2020.06.018","article-title":"Relative and absolute risk reductions in cardiovascular and kidney outcomes with canagliflozin across KDIGO risk categories: findings from the CANVAS program","volume":"77","author":"Neuen","year":"2021","journal-title":"Am J Kidney Dis."},{"issue":"19","key":"B30-20261017","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.jacc.2023.03.390","article-title":"Efficacy of empagliflozin in patients with heart failure across kidney risk categories","volume":"81","author":"Butler","year":"2023","journal-title":"J Am Coll Cardiol."},{"issue":"4","key":"B31-20261017","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation."},{"issue":"1","key":"B32-20261017","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","article-title":"Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial","volume":"8","author":"Mc Causland","year":"2023","journal-title":"JAMA Cardiol."},{"issue":"8","key":"B33-20261017","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2337\/dc21-0076","article-title":"The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58","volume":"44","author":"Mosenzon","year":"2021","journal-title":"Diabetes Care."},{"issue":"11","key":"B34-20261017","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1681\/ASN.2019010064","article-title":"Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program","volume":"30","author":"Neuen","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"B35-20261017","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1001\/jamacardio.2022.2924","article-title":"Association of empagliflozin treatment with albuminuria levels in patients with heart failure: a secondary analysis of EMPEROR-pooled","volume":"7","author":"Ferreira","year":"2022","journal-title":"JAMA Cardiol."},{"issue":"2","key":"B36-20261017","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"New Engl J Med."},{"issue":"19","key":"B37-20261017","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl J Med."},{"issue":"4","key":"B38-20261017","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl J Med."},{"issue":"10193","key":"B39-20261017","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"issue":"10313","key":"B40-20261017","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet."},{"issue":"24","key":"B41-20261017","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"New Engl J Med."},{"issue":"5","key":"B42-20261017","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"New Engl J Med."},{"issue":"7","key":"B43-20261017","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.ekir.2024.04.028","article-title":"Effects of once-weekly semaglutide on kidney disease outcomes by KDIGO risk category in the SUSTAIN 6 trial","volume":"9","author":"Tuttle","year":"2024","journal-title":"Kidney Int Rep."},{"issue":"10193","key":"B44-20261017","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"issue":"9","key":"B45-20261017","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"New Engl J Med."},{"issue":"11","key":"B46-20261017","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"7","key":"B47-20261017","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med."},{"issue":"18","key":"B48-20261017","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jacc.2025.03.009","article-title":"Interplay of chronic kidney disease and the effects of tirzepatide in patients with heart failure, preserved ejection fraction, and obesity","volume":"85","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol."},{"issue":"23","key":"B49-20261017","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"New Engl J Med."},{"issue":"24","key":"B50-20261017","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"New Engl J Med."},{"issue":"2","key":"B51-20261017","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","article-title":"Finerenone and kidney outcomes in patients with heart failure","volume":"85","author":"Causland","year":"2025","journal-title":"J Am Coll Cardiol."},{"issue":"20","key":"B52-20261017","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"B53-20261017","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","article-title":"Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction","volume":"125","author":"Rossignol","year":"2012","journal-title":"Circulation."},{"issue":"17","key":"B54-20261017","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (eplerenone in mild patients hospitalization and SurvIval study in heart failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"B55-20261017","doi-asserted-by":"crossref","first-page":"e005288","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288","article-title":"Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction","volume":"11","author":"Selvaraj","year":"2018","journal-title":"Circ Heart Fail."},{"issue":"3","key":"B56-20261017","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting\u2013enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"New Engl J Med."},{"issue":"19","key":"B57-20261017","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"New Engl J Med."},{"issue":"10","key":"B58-20261017","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"New Engl J Med."},{"issue":"9590","key":"B59-20261017","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet."},{"issue":"15","key":"B60-20261017","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"New Engl J Med."},{"issue":"1","key":"B61-20261017","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/j.ajkd.2019.05.010","article-title":"Trends in kidney function outcomes following RAAS inhibition in patients with heart failure with reduced ejection fraction","volume":"75","author":"McCallum","year":"2020","journal-title":"Am J Kidney Dis."},{"issue":"16","key":"B62-20261017","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.109.853648","article-title":"Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure","volume":"120","author":"Anand","year":"2009","journal-title":"Circulation."},{"issue":"9","key":"B63-20261017","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1161\/CIRCULATIONAHA.121.052792","article-title":"Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease","volume":"145","author":"Beldhuis","year":"2022","journal-title":"Circulation."},{"issue":"20","key":"B64-20261017","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting\u2013enzyme inhibition in stable coronary artery disease","volume":"351","author":"Braunwald","year":"2004","journal-title":"New Engl J Med."},{"issue":"23","key":"B65-20261017","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure","volume":"316","year":"1987","journal-title":"New Engl J Med."},{"issue":"9399","key":"B66-20261017","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(03)14974-4","article-title":"The EUROPA trial","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet."},{"issue":"17","key":"B67-20261017","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"New Engl J Med."},{"issue":"11","key":"B68-20261017","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"New Engl J Med."},{"issue":"13","key":"B69-20261017","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction","volume":"142","author":"Mc Causland","year":"2020","journal-title":"Circulation."},{"issue":"6","key":"B70-20261017","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:01:04Z","timestamp":1792249264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001170"}},"subtitle":["Ready for Primetime?"],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":69,"URL":"https:\/\/doi.org\/10.2215\/cjn.0000001170","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}